+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Canada Glucose Monitoring Device Market, By Region, Competition, Forecast & Opportunities, 2020-2030F

  • PDF Icon

    Report

  • 70 Pages
  • May 2025
  • Region: Canada
  • TechSci Research
  • ID: 5892167
Free Webex Call
10% Free customization
Free Webex Call

Speak directly to the analyst to clarify any post sales queries you may have.

10% Free customization

This report comes with 10% free customization, enabling you to add data that meets your specific business needs.

The Canada Glucose Monitoring Device Market was valued at USD 1.23 Billion in 2024, and is expected to reach USD 2.54 Billion by 2030, rising at a CAGR of 12.85%. The market is witnessing significant expansion driven by rapid technological advancements and the rising prevalence of diabetes across the country. With diabetes recognized as a pressing public health concern, demand for efficient glucose monitoring tools has surged. According to Health Canada, the global diabetic population is expected to more than double by 2050, underscoring the urgent need for accessible monitoring solutions. As a major contributor to global morbidity and mortality, diabetes has propelled the adoption of devices like continuous and flash glucose monitors, which offer real-time data and enable proactive disease management.

Key Market Drivers

Rising Prevalence of Diabetes in Canada

The growing number of diabetes cases across Canada is a critical factor driving the glucose monitoring device market. By 2020-2021, approximately 3.7 million Canadians, or 9.4% of the population aged one and above, were diagnosed with diabetes, a figure that climbs to 27% among those aged 65 and older. This demographic shift underscores the escalating need for effective blood sugar monitoring tools. Devices such as continuous glucose monitors (CGMs) and flash glucose monitors (FGMs) have become essential for real-time tracking and management of glucose levels. They support timely interventions and help mitigate complications like cardiovascular disease, kidney damage, and neuropathy, thereby improving patient outcomes and quality of life.

Key Market Challenges

High Cost of Advanced Monitoring Devices

The cost of advanced glucose monitoring technologies remains a major hurdle to widespread use. While some government programs offer financial assistance, not all individuals qualify, and personal expenses can be steep. For instance, individuals with type 1 diabetes in Alberta may face up to $7,000 in annual out-of-pocket expenses, while those with type 2 diabetes could spend as much as $6,000. These costs include the initial device, sensors, and transmitters, which can be financially burdensome for patients lacking sufficient insurance coverage. This financial barrier often restricts access to newer technologies, affecting diabetes care and control among economically vulnerable populations.

Key Market Trends

Adoption of Advanced Glucose Monitoring Technologies

A prominent trend in the Canadian market is the increasing shift towards advanced glucose monitoring systems, particularly CGMs. These devices deliver continuous glucose readings, offering superior glycemic management and reducing complications such as hypo- and hyperglycemia. Compared to traditional finger-prick methods, CGMs enhance user convenience and improve quality of life. Integration with insulin pumps and mobile apps has enabled real-time data sharing and automated insulin delivery, allowing healthcare providers to personalize treatment plans more effectively. As awareness of these benefits grows, the uptake of advanced glucose monitoring technologies is expected to rise steadily across Canada.

Key Market Players

  • Medtronic of Canada Ltd
  • Abbott Canada.
  • Johnson & Johnson Inc/Canada
  • Braun of Canada
  • F. Hoffmann-La Roche Limited.
  • Ascensia Diabetes Care.
  • Sanofi-Aventis Canada Inc.
  • Eli Lilly Canada Inc.

Report Scope:

In this report, the Canada glucose monitoring device market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Canada Glucose Monitoring Device Market, By Product Type:

  • Self-Blood Glucose Monitoring Devices
  • Continuous Glucose Monitoring Devices

Canada Glucose Monitoring Device Market, By Application:

  • Type 1 Diabetes
  • Type 2 Diabetes
  • Gestational Diabetes

Canada Glucose Monitoring Device Market, By End User:

  • Home Care Settings
  • Hospital
  • Others

Canada Glucose Monitoring Device Market, By Region:

  • Ontario
  • Quebec
  • Alberta
  • British Columbia
  • Saskatchewan and Manitoba
  • Rest of Canada

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Canada Glucose Monitoring Device Market.

Available Customizations:

With the given market data, the publisher offers customizations according to a company's specific needs. The following customization options are available for the report.

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

This product will be delivered within 1-3 business days.

Table of Contents

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, and Trends
4. Voice of Customer
5. Canada Glucose Monitoring Device Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product Type (Self Blood Glucose Monitoring Devices v/s Continuous Glucose Monitoring Devices)
5.2.2. By Application (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes)
5.2.3. By End User (Home Care Settings, Hospital, Others)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. Ontario Glucose Monitoring Device Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product Type
6.2.2. By Application
6.2.3. By End User
7. Quebec Glucose Monitoring Device Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product Type
7.2.2. By Application
7.2.3. By End User
8. Alberta Glucose Monitoring Device Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product Type
8.2.2. By Application
8.2.3. By End User
9. British Columbia Glucose Monitoring Device Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product Type
9.2.2. By Application
9.2.3. By End User
10. Saskatchewan and Manitoba Glucose Monitoring Device Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product Type
10.2.2. By Application
10.2.3. By End User
11. Rest of Canada Glucose Monitoring Device Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Product Type
11.2.2. By Application
11.2.3. By End User
12. Market Dynamics
12.1. Drivers
12.2. Challenges
13. Market Trends & Developments
13.1. Merger & Acquisition (If Any)
13.2. Product Launches (If Any)
13.3. Recent Developments
14. Porters Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products/Services
15. Competitive Landscape
15.1. Medtronic of Canada Ltd
15.1.1. Business Overview
15.1.2. Company Snapshot
15.1.3. Products & Services
15.1.4. Financials (As Reported)
15.1.5. Recent Developments
15.1.6. Key Personnel Details
15.1.7. SWOT Analysis
15.2. Abbott Canada.
15.3. Johnson & Johnson Inc/Canada
15.4. Braun of Canada
15.5. F. Hoffmann-La Roche Limited.
15.6. Ascensia Diabetes Care.
15.7. Sanofi-Aventis Canada Inc.
15.8. Eli Lilly Canada Inc.
16. Strategic Recommendations17. About the Publisher & Disclaimer

Companies Mentioned

  • Medtronic of Canada Ltd
  • Abbott Canada.
  • Johnson & Johnson Inc/Canada
  • Braun of Canada
  • F. Hoffmann-La Roche Limited.
  • Ascensia Diabetes Care.
  • Sanofi-Aventis Canada Inc.
  • Eli Lilly Canada Inc.

Table Information